New class of anticancer ‘stealth’ drug proceeds to clinical development
23 February 2011
The first of an exciting new class of anti-cancer drugs designed in New Zealand will proceed to clinical development in the United States, following the announcement today of a deal between Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo).
read more